Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes MellitusA Matching-Adjusted Indirect Comparison of Randomized Trials

被引：0
|
作者：
James E. Signorovitch
Eric Q. Wu
Elyse Swallow
Evan Kantor
Liangyi Fan
Jean-Bernard Gruenberger
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Novartis Pharma AG,undefined
来源：
Clinical Drug Investigation | 2011年 / 31卷
关键词：
Fasting Plasma Glucose; Glycaemic Control; Sitagliptin; Vildagliptin; Individual Patient Data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and Objective: Vildagliptin and sitagliptin are oral dipeptidyl peptidase 4 inhibitors approved in Japan for the treatment of type 2 diabetes mellitus when adequate glycaemic control is not achieved with diet, exercise or sulphonylureas. The aim of this study was to compare 12-week glycaemic control with vildagliptin 50 mg twice daily versus sitagliptin 50 or 100 mg once daily in Japanese patients with type 2 diabetes.
引用
收藏
页码：665 / 674
页数：9
相关论文
共 50 条
  • [21] Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) : 2055 - 2067
  • [22] Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events
    Ahren, Bo
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 23 (04) : 487 - 498
  • [23] Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes
    Yamaguchi, Masayuki
    Saji, Takami
    Mita, Sachiko
    Kulmatycki, Kenneth
    He, Yan-Ling
    Furihata, Kenichi
    Sekiguchi, Kaneo
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (08) : 641 - 651
  • [24] Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
    Vanja Sikirica
    Robert L. Findling
    James Signorovitch
    M. Haim Erder
    Ryan Dammerman
    Paul Hodgkins
    Mei Lu
    Jipan Xie
    Eric Q. Wu
    CNS Drugs, 2013, 27 : 943 - 953
  • [25] Predictive clinical characteristics for the efficacy of vildagliptin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicenter study
    Okayama N.
    Imaeda K.
    Kato T.
    Iwase S.
    Ohguchi H.
    Joh T.
    Hayashi Y.
    Akao M.
    Ogawa K.
    Hachiya M.
    Hattori R.
    Kimura R.
    Yasui S.
    Ando M.
    Jinno Y.
    Takahashi N.
    Shimizu M.
    Miyachi N.
    Diabetology International, 2013, 4 (3) : 179 - 185
  • [26] Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
    Ayako Fuchigami
    Fumika Shigiyama
    Toru Kitazawa
    Yosuke Okada
    Takamasa Ichijo
    Mariko Higa
    Toru Hiyoshi
    Ikuo Inoue
    Kaoru Iso
    Hidenori Yoshii
    Takahisa Hirose
    Naoki Kumashiro
    Cardiovascular Diabetology, 19
  • [27] Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
    Fuchigami, Ayako
    Shigiyama, Fumika
    Kitazawa, Toru
    Okada, Yosuke
    Ichijo, Takamasa
    Higa, Mariko
    Hiyoshi, Toru
    Inoue, Ikuo
    Iso, Kaoru
    Yoshii, Hidenori
    Hirose, Takahisa
    Kumashiro, Naoki
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [28] Comparison of Efficacy and Safety of Sitagliptin and Glimepiride in Treatment of Type 2 Diabetes Mellitus
    Hussain, Shabir
    Mustafa, Amjad
    Mumtaz, Arif
    Shaheen, Ghazala
    Qaiser, Fawad
    Soban, Mohammad
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (10): : 2800 - 2803
  • [29] Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes
    Ohta, Akio
    Ohshige, Toshihiko
    Sakai, Kensuke
    Nakamura, Yuta
    Tenjin, Ayumi
    Tsukiyama, Shuichi
    Terashima, Yuko
    Matsubara, Fumiaki
    Kawata, Takehiro
    Nagai, Yoshio
    Tanaka, Yasushi
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (17) : 2315 - 2322
  • [30] Efficacy and Safety of Vildagliptin for Type 2 Diabetes in Patients With Diabetic Kidney Disease
    Mima, Akira
    Nakamoto, Takahiro
    Saito, Yuta
    Matsumoto, Keishi
    Lee, Shinji
    IN VIVO, 2024, 38 (04): : 1829 - 1833
12345